Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

36.85
Delayed Data
As of 3:59pm ET
 -0.62 / -1.65%
Today’s Change
33.60
Today|||52-Week Range
50.40
-3.41%
Year-to-Date
K-Mart to Sell Cheaper EpiPen Alternative
9:45am / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug To...
Apr 13 / Zacks.com - Paid Partner Content
Sanofi Sues Mylan Over EpiPen Practices
Apr 24 / TheStreet.com - Paid Partner Content
Mylan Down on FDA Warning Letter to Manufacturing Facility
Apr 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close37.47
Today’s open37.47
Day’s range36.57 - 37.50
Volume5,844,133
Average volume (3 months)5,546,310
Market cap$20.1B
Dividend yield--
Data as of 3:59pm ET, 04/25/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)+8.46%
Earnings growth (next 5 years)+4.40%
Revenue growth (last year)+17.44%
P/E ratio15.9
Price/Sales1.79
Price/Book1.80

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.67+0.72%
INCYIncyte Corp+0.48+0.39%
ALXNAlexion Pharmaceutic...+1.01+0.84%
ZTSZoetis Inc+0.13+0.24%
Data as of 4:03pm ET, 04/25/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)$0.99
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts


Search for Jobs